Verdinexor (KPT-335)
Solid Tumors & Lymphoma
Phase 1Next-generation SINE compound
Key Facts
Indication
Solid Tumors & Lymphoma
Phase
Phase 1
Status
Next-generation SINE compound
Company
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profile